Strides Pharma today announced that it has developed and commercialized Favipiravir Antiviral tablets, which is a generic version of Avigan of Toyama Chemical, Japan.
Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan. And in February, after the outbreak of coronavirus, Favipiravir was studied in China and several other countries as an experimental treatment of Covid-19. "The drug has demonstrated positive outcomes, including a reduction in the duration of Covid-19 and improved lung conditions for the patients," Strides Pharma said.
Shares of Strides Pharma today zoomed 18% to ₹442. In comparison, the Sensex was up over 1% in afternoon trade. Strides has developed Favipiravir tablets in 400mg